Mumbai, July 26, 2024: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited
consolidated financial results for the quarter ended June 30th, 2024.
▪ One-India: India Branded Prescription Business grew at a healthy rate of 10% YoY. Overall One India
growth was offset by softness in Trade Generics Business owing to distribution model change.
▪ North America: All-time high revenue at $ 250 Mn up by 13% YoY supported by traction in
differentiated portfolio.
▪ South Africa: Momentum continues with revenue growth at 19% in local currency terms. Prescription
business ranked #1 in the market##
▪ R&D investments: stand at INR 353 Cr or 5.3 % of sales, higher by 1% YoY driven by product filings
and developmental efforts.
▪ Strong net cash: Net cash position of INR 8,449 Cr; Debt primarily includes lease liabilities and
working capital requirements.
▪ Compliance update: Patalganga and Kurkumbh facilities were classified as ‘VAI’ by USFDA.
## As per IQVIA MAT May 2024
“I am pleased to share that we continue to make considerable progress across our focused
markets. In Q1 FY25, we recorded revenue growth of 7% over last year with EBITDA margin of 25.6%
driven by mix and other operational efficiencies. Our One-India business continued on its growth
trajectory during the quarter, led by Branded Prescription which grew at 10%. Our concentrated
focus and execution in differentiated portfolio have further strengthened the US business which
yet again posted all-time high quarterly revenue at $ 250 Mn. In South Africa, we recorded a solid
growth of 19% YoY in local currency terms, led by Private Market. Going ahead, focus will be on
growing our key markets, further building our flagship brands, investing in future pipeline as well as
focusing on resolutions on the regulatory front”.
Umang Vohra
MD and Global CEO, Cipla Ltd
